BACKGROUND: Epicardial catheter ablation has been shown to be an effective strategy for treating ventricular arrhythmias (VA). We investigated the efficacy and safety from a tertiary referral center in Taiwan. METHODS: From 2010 to 2016, patients undergoing epicardial ablation for VAs were consecutively enrolled. The clinical characteristics, disease entity, electrophysiological studies, and ablation outcome were extracted for further analysis. RESULTS: A total of 80 patients were eligible, including 34 patients for arrhythmogenic right ventricular cardiomyopathy (ARVC), 16 for Brugada syndrome (BrS), 13 for idiopathic VAs, 11 for idiopathic dilated cardiomyopathy (IDCM), 2 for ischemic cardiomyopathy, and 4 for other nonischemic cardiomyopathies (NICM). Epicardial ablation rendering VAs non-inducible was achieved in 78 patients (97.5%). There were no procedure-related deaths. Major complications were reported in 8 (10.0%) patients, including an acute hemopericardium in 5 (6.3%), delayed tamponade in 1 (1.3%), hemothorax in 1 (1.3%), and major pericardial reaction in 1 (1.3%). Two (2.7%) patients died due to causes other than procedure-related deaths. After a mean follow-up of 31 ± 15 months, 20 patients (25.0%) presented with VA recurrences, including 13 with ARVC, 1 with BrS, 1 with idiopathic VAs, 4 with IDCM, and 1 with other NICM. CONCLUSIONS: In this tertiary referral center's experience, the complication rate of an epicardial approach was acceptable. Patients with NICM displayed a growing trend for a referral for epicardial ablation. The long-term follow-up demonstrated that an epicardial ablation for idiopathic VAs and BrS was associated with a better prognosis than that for the other etiologies.
BACKGROUND: Epicardial catheter ablation has been shown to be an effective strategy for treating ventricular arrhythmias (VA). We investigated the efficacy and safety from a tertiary referral center in Taiwan. METHODS: From 2010 to 2016, patients undergoing epicardial ablation for VAs were consecutively enrolled. The clinical characteristics, disease entity, electrophysiological studies, and ablation outcome were extracted for further analysis. RESULTS: A total of 80 patients were eligible, including 34 patients for arrhythmogenic right ventricular cardiomyopathy (ARVC), 16 for Brugada syndrome (BrS), 13 for idiopathic VAs, 11 for idiopathic dilated cardiomyopathy (IDCM), 2 for ischemic cardiomyopathy, and 4 for other nonischemic cardiomyopathies (NICM). Epicardial ablation rendering VAs non-inducible was achieved in 78 patients (97.5%). There were no procedure-related deaths. Major complications were reported in 8 (10.0%) patients, including an acute hemopericardium in 5 (6.3%), delayed tamponade in 1 (1.3%), hemothorax in 1 (1.3%), and major pericardial reaction in 1 (1.3%). Two (2.7%) patients died due to causes other than procedure-related deaths. After a mean follow-up of 31 ± 15 months, 20 patients (25.0%) presented with VA recurrences, including 13 with ARVC, 1 with BrS, 1 with idiopathic VAs, 4 with IDCM, and 1 with other NICM. CONCLUSIONS: In this tertiary referral center's experience, the complication rate of an epicardial approach was acceptable. Patients with NICM displayed a growing trend for a referral for epicardial ablation. The long-term follow-up demonstrated that an epicardial ablation for idiopathic VAs and BrS was associated with a better prognosis than that for the other etiologies.
Authors: Rong Bai; Dimpi Patel; Luigi Di Biase; Tamer S Fahmy; Marketa Kozeluhova; Subramanya Prasad; Robert Schweikert; Jennifer Cummings; Walid Saliba; Michelle Andrews-Williams; Sakis Themistoclakis; Aldo Bonso; Antonio Rossillo; Antonio Raviele; Claus Schmitt; Martin Karch; Jorge A Salerno Uriarte; Patrick Tchou; Mauricio Arruda; Andrea Natale Journal: J Cardiovasc Electrophysiol Date: 2006-06-27
Authors: Mathew D Hutchinson; Edward P Gerstenfeld; Benoit Desjardins; Rupa Bala; Michael P Riley; Fermin C Garcia; Sanjay Dixit; David Lin; Wendy S Tzou; Joshua M Cooper; Ralph J Verdino; David J Callans; Francis E Marchlinski Journal: Circ Arrhythm Electrophysiol Date: 2010-12-03
Authors: Glenn M Polin; Haris Haqqani; Wendy Tzou; Mathew D Hutchinson; Fermin C Garcia; David J Callans; Erica S Zado; Francis E Marchlinski Journal: Heart Rhythm Date: 2010-11-27 Impact factor: 6.343
Authors: Kyoko Soejima; William G Stevenson; John L Sapp; Andrew P Selwyn; Gregory Couper; Laurence M Epstein Journal: J Am Coll Cardiol Date: 2004-05-19 Impact factor: 24.094
Authors: Kurt C Roberts-Thomson; Daniel Steven; Jens Seiler; Keiichi Inada; Bruce A Koplan; Usha B Tedrow; Laurence M Epstein; William G Stevenson Journal: Circulation Date: 2009-09-28 Impact factor: 29.690
Authors: Pasquale Santangeli; Erica S Zado; Gregory E Supple; Haris M Haqqani; Fermin C Garcia; Cory M Tschabrunn; David J Callans; David Lin; Sanjay Dixit; Mathew D Hutchinson; Michael P Riley; Francis E Marchlinski Journal: Circ Arrhythm Electrophysiol Date: 2015-11-06
Authors: Fa Po Chung; Chin Yu Lin; Yenn Jiang Lin; Shih Lin Chang; Li Wei Lo; Yu Feng Hu; Ta Chuan Tuan; Tze Fan Chao; Jo Nan Liao; Ting Yung Chang; Shih Ann Chen Journal: Korean Circ J Date: 2018-10 Impact factor: 3.243